J&J Innovative Medicine Europe, Middle East & Africa (EMEA)’s Post

🔬 The Vital Role of Genetic Testing in Cancer Immunotherapy 🔬   At GoPath Diagnostics, we integrate advanced genetic testing with innovative cancer treatments to offer personalized care. This blog highlights how germline and somatic genetic tests guide treatment decisions and transform immunotherapy. Discover how these tests help oncologists tailor therapies like checkpoint inhibitors and CAR T-cell therapy, ensuring the best outcomes for cancer patients.   Read the full blog: https://lnkd.in/g7ur2WDR #GeneticTesting #CancerCare #Immunotherapy #PrecisionMedicine

Cancer treatment has seen significant advancements, largely due to the growth of genetic testing, which provides the insights necessary to identify tumor mutations for targeted therapy and significantly reduces the time between diagnosis and treatment. In an exclusive with The Cancer Letter, Avalon Vice President of Product Matt Ingram highlights recent studies on non-small cell lung cancer (NSCLC) patients that indicate the need for better integration of genetic testing into treatment plans and how an oncology drug management program, overseen by a third-party partner, could help eliminate unnecessary spending, ensure proper genetic testing, improved patient outcomes, and cost savings. Read more: https://ow.ly/E4mo50SS0k1 #AvalonHCS #LabBenefitManagement #ValueDrivenCare

📢 Publication alert!   💪 Exciting news for endometrial cancer patients! 💫 Immunotherapy combined with chemotherapy is showing promise in improving progression-free survival. Thanks to new biomarkers, we're getting better at selecting the right patients, even those with microsatellite-stable tumors (MSS). 🎯 🧬 The latest findings from the MITO END-3 trial shed light on how certain gene mutations like TP53, PIK3CA, ARID1A, and PTEN impact the effectiveness of Avelumab. Good news: ARID1A and PTEN mutations seem to boost treatment effects! However, TP53 mutations might mean a poorer response to avelumab.  Thanks to the panel and congratulations to the authors on this great achievement! It was amazing for Polistudium to be part of it! #EndometrialCancer #Immunotherapy #ResearchBreakthrough #Scicomm #Medicalwriting Read more here 👇 https://bit.ly/44tjdjG

🔬 A Breakthrough Genetic Test Unveiled for Breast Cancer Treatment! 🌟 Researchers at UCSF have developed a new genetic test, a significant step forward for precision medicine. 🚀 This promises to enhance treatment programs, sparing patients from ineffective, potentially toxic drugs while guiding them toward more effective alternatives. More study details are summarized in the article " Genetic Test Can Identify Triple Negative Breast Cancer Treatment Responders"📰 #BreastCancerAwareness #PrecisionMedicine #MedicalBreakthroughs https://lnkd.in/gwJfbnS7

For over 2 decades, cancer therapies have focused on inhibiting oncogenes. Yet many oncogenes are vulnerable not just to inhibition but also to activation – we call this surprising vulnerability ‘activation lethality.’ When oncogenes are overactivated, they overload cell stress pathways, and drugs that overactivate #cancer targets are selectively lethal to cancers with mutations that push them near the limits of tolerable pathway activity. Delphia’s approach integrates #tumor genetics, innovative functional genomic techniques, and studies on inhibitor drug resistance to identify targets that drive #activationlethality. You can learn more at https://lnkd.in/gY2bTe4R.

Innovation in diagnostics is always exciting because we’re discovering new ways to provide better care for our patients. An example is companion diagnostics - tests used alongside treatments to identify patients likely to benefit based on specific biomarkers or genetic mutations. They enable personalised healthcare solutions by matching patients with therapies most effective for their unique biological profiles. Innovations in companion #diagnostics are helping reclassify patients with HER2-low breast cancer, like Enisa Besic, and making them eligible for targeted therapy. This shift in how pathologists look at HER2 biomarker expression means clinicians can offer personalised, HER2-targeted therapy options to more patients. Learn more about Enisa’s journey, and the powerful role of diagnostics here: https://lnkd.in/gVGbfAYZ #breastcancer #HER2 #biomarkers #valueofdiagnostics

⚡New data from the MITO END-3 trial Out of 125 randomized patients, 109 underwent next-generation sequencing (NGS) analysis and 102 had MSI testing. The Cancer Genome Atlas (TCGA) revealed 29 cases of MSI-H, with high TMB observed in all MSI-H patients. Avelumab's effect on progression-free survival varied significantly across TCGA categories, with favourable outcomes in MSI-H and worse outcomes in MSS/TP53 mut patients. Additionally, ARID1A and PTEN mutations were associated with a positive treatment effect. Check out the article for more details: https://ow.ly/6uFK50Rxhhi

Faster Results for Clinicians Treating Breast Cancer Patients Waiting for test results can be a big setback in clinical cancer care, especially if preventative treatment may be urgently required. The Everything Genetic 12 Gene Breast Cancer Panel is delivered from a UK laboratory, allowing you to receive clinically actionable results in just 2–3 weeks. This allows you to quickly determine best next steps for treatments and implement the right preventative care for your patients. By identifying the disease-causing variant, the 12 Gene Breast Cancer Panel can also guide testing and management of at-risk relatives. Find out more: https://buff.ly/3xbhT8d Listen what our Medical Director, Dr James Mackay, has to say about this test in the video below ⬇️ #BreastCancer #BreastCancerTest #GeneticTestForBreastCancer #12GenePanel #UKGeneticTest #GeneticTesting #NGSTesting #GeneticTest #BreastCancerRiskTest #BreastCancerRisk #CancerPrevention #CancerTreatment #CancerDiagnosis

Can a simple tumour tissue test help identify the very best treatment for a cancer patient? Yes! This powerful, brand-new tumour RNA expression test is a game-changer for cancer patients and their doctors and looks at tumour based expression of just under 21,000 genes. It can help determine the exact right treatment(s) for a patient… (More accurately than DNA genetic testing alone!) CTOAM’s cancer expert, Alex Rolland, made this video to explain more: The main takeaway? If you're not using this test in your diagnosis, you're likely missing out on better cancer treatments… Treatments that could help you live significantly longer, and with fewer side-effects, than the treatment you're currently on… And that could even help you become cancer-free, like many of our patients! Apply for a Precision Second Opinion to find out what your best treatment options are, today: https://buff.ly/2sDA3yx #PrecisionCancerMedicine #HopeIsHere

Can a simple tumour tissue test help identify the very best treatment for a cancer patient? Yes! This powerful, brand-new tumour RNA expression test is a game-changer for cancer patients and their doctors and looks at tumour based expression of just under 21,000 genes. It can help determine the exact right treatment(s) for a patient… (More accurately than DNA genetic testing alone!) CTOAM’s cancer expert, Alex Rolland, made this video to explain more: The main takeaway? If you're not using this test in your diagnosis, you're likely missing out on better cancer treatments… Treatments that could help you live significantly longer, and with fewer side-effects, than the treatment you're currently on… And that could even help you become cancer-free, like many of our patients! Apply for a Precision Second Opinion to find out what your best treatment options are, today: https://buff.ly/2sDA3yx #PrecisionCancerMedicine #HopeIsHere